Tina St. Leger compensation by year
Immunocore Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $338,458 | $361,692 | $374,946 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $250,890 |
| Option awards | $529,992 | $572,873 | $376,357 |
| Non-equity incentive | $155,691 | $160,274 | $179,974 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $14,976 | $21,032 | $23,150 |
| Total | $1,039,117 | $1,115,871 | $1,204,261 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunocore Holdings plc DEF 14A filed April 16, 2026, accession 0001140361-26-015122, and prior-year filings.
How this page was built: the Immunocore Holdings plc filed document, accession 0001140361-26-015122. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 8,476 | $294,202 | — |
| Option | 8,750 | — | $29.87 |
| Option | 4,168 | — | $64.53 |
| Option | 7,966 | — | $70.50 |
| Option | 23,212 | — | $29.60 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Immunocore Holdings plc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Immunocore’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Bahija Jallal | Chief Executive Officer | $10,885,268 |
| Travis Coy | Chief Financial Officer and Head of Corporate Development | $5,171,209 |
| David Berman | Former Executive Vice President, Head of Research & Development | $4,278,988 |
| Tina St. Leger · this page | Chief Human Resources Officer | $1,204,261 |
Tina St. Leger's compensation dossier, Immunocore
You have read Tina St. Leger's totals and holdings. The dossier adds each equity grant Immunocore disclosed for Tina St. Leger and Immunocore's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Immunocore compensation record
free company briefThis page is one person within Immunocore's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Immunocore proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Immunocore's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunocore's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.